Countdown on Avastin

With the biotech sector desperate for positive product news, attention will be turning to Avastin from Genentech Inc., which is aiming to disclose its first Phase III data by the end of the quarter, in breast cancer.


Read the full 377 word article

How to gain access

Continue reading with a
two-week free trial.